Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study

被引：2
|
作者：
Matsumoto, Teppei [1 ]
Hatakeyama, Shingo [1 ]
Narita, Takuma [1 ]
Yoneyama, Takahiro [1 ]
Hashimoto, Yasuhiro [1 ]
Ohyama, Chikara [1 ]
机构：
[1] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2019年 / 26卷 / 04期
基金：
日本学术振兴会;
关键词：
discontinuation; dutasteride; lower urinary symptom; oxidative stress; tadalafil; MEN; DISCONTINUATION; INHIBITOR; BLOCKER;
D O I：
10.1111/iju.13908
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：522 / 523
页数：2
相关论文
共 50 条
  • [1] Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study
    Donatucci, Craig F.
    Brock, Gerald B.
    Goldfischer, Evan R.
    Pommerville, Peter J.
    Elion-Mboussa, Albert
    Kissel, Jay D.
    Viktrup, Lars
    BJU INTERNATIONAL, 2011, 107 (07) : 1110 - 1116
  • [2] Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Daisuke Gotoh
    Kazumasa Torimoto
    Yosuke Morizawa
    Shunta Hori
    Yasushi Nakai
    Makito Miyake
    Kiyohide Fujimoto
    BMC Research Notes, 15
  • [3] Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Gotoh, Daisuke
    Torimoto, Kazumasa
    Morizawa, Yosuke
    Hori, Shunta
    Nakai, Yasushi
    Miyake, Makito
    Fujimoto, Kiyohide
    BMC RESEARCH NOTES, 2022, 15 (01)
  • [4] Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia
    Rohrbough, C. R.
    Colgan, Bridget
    Gasser, Ollie
    AMERICAN FAMILY PHYSICIAN, 2024, 109 (01) : 83 - 84
  • [5] Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia
    McVary, Kevin T.
    Roehrborn, Claus G.
    Kaminetsky, Jed C.
    Auerbach, Stephen M.
    Wachs, Barton
    Young, Jay M.
    Esler, Anne
    Sides, Gregory D.
    Denes, Bela S.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 1401 - 1407
  • [6] Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
    Kosilov, Kirill, V
    Kuzina, Irina G.
    Kuznetsov, Vladimir
    Kosilova, Ekaterina K.
    PROSTATE INTERNATIONAL, 2020, 8 (02) : 78 - 84
  • [7] Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Gonzalez, Ricardo R.
    Kaplan, Steven A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 609 - 617
  • [8] Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Kose, Gokhan
    Tekin, Ilteris
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2007, 6 (01): : 34 - 36
  • [9] Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled, Open-Label Non-Inferiority Study
    Lee, Hyo Serk
    Kim, Sae Woong
    Oh, Seung-June
    Choo, Myung-Soo
    Lee, Kyu-Sung
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (03) : 178 - 183
  • [10] Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
    Ahmad, Malik Suhail
    Dar, Yaser Ahmad
    Khawaja, Abdul Rauf
    Para, Sajad Ahamd
    Malik, Sajad Ahamd
    Wani, Mohammad Saleem
    Bhat, Arif Hamid
    Wani, Prince Muzaffar
    UROLOGY ANNALS, 2022, 14 (03) : 236 - 240
12345